Hepatitis B

Hepatitis B features

• 

  Management of HIV and hepatitis B or C co-infection in resource-limited settings

  Review of management of HIV and hepatitis co-infection with particular focus on antiretroviral therapy and liver disease in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  Viral hepatitis in low and middle-income settings

  Management of HIV and hepatitis B or C co-infection in resource-limited settings....

  From:  HIV & AIDS treatment in practice

Hepatitis B news from aidsmap

• Elevated prevalence of HIV and viral hepatitis in men injecting anabolic steroids

  Addressing a topic that has received remarkably little research attention over the years, Dr Vivian Hope of Public Health England told the British HIV Association conference yesterday that injection of image- and performance-enhancing drugs is rising in England and ...

  18 April 2013 | Roger Pebody

• Liver disease a major cause of illness and death across the EU: action needed to save lives

  Liver disease is the cause of a considerable burden of illness across the European Union (EU), investigators report in The Journal of Hepatology. The authors calculate that 170,000 deaths each year are attributable to liver cirrhosis, with 47,000 of these ...

  16 April 2013 | Michael Carter

• Tenofovir and 3TC prevent new hepatitis B infections in gay men living with HIV

  The inclusion of 3TC or tenofovir in antiretroviral treatment regimens reduces the risk of infection with hepatitis B virus (HBV) for gay men living with HIV who have not been vaccinated against HBV, Japanese investigators report in the online ...

  03 April 2013 | Michael Carter

• Drinking coffee halves the risk of liver cancer

  Coffee consumption reduces the risk of liver cancer by approximately 50%, the results of a meta-analysis published in the online journal BMC Gastroenterology show. A total of 16 studies published before May 2012 were included in the analysis. Closer examination ...

  02 April 2013 | Michael Carter

• Dually active antiretroviral therapy protects against hepatitis B infection

  Use of antiretroviral therapy that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that people living with HIV will become infected with HBV – in effect acting as HBV pre-exposure prophylaxis (PrEP) ...

  07 March 2013 | Liz Highleyman

• Triple trouble: infection with hepatitis B increases risk of death for people with HIV and hepatitis C co-infection

  Infection with hepatitis B virus (HBV) is associated with a poorer prognosis for people living with HIV who are co-infected with hepatitis C virus (HCV), Spanish investigators report in a study published in the online edition of AIDS. After taking ...

  19 February 2013 | Michael Carter

• Combining tenofovir with FTC or 3TC boosts chances of HBV suppression for people co-infected with HIV

  A study involving people co-infected with HIV and hepatitis B virus (HBV) shows that antiretroviral therapy that combines tenofovir with FTC or 3TC has the best chance of suppressing HBV replication to undetectable levels. The research is published in ...

  19 February 2013 | Michael Carter

• Hepatitis B treatment and care in the UK need to evolve to keep pace with the global epidemic

  “Persistent HBV [hepatitis B virus] infection has changed its face in the UK,” research published in the online edition of Clinical Infectious Diseases shows. The study found considerable diversity in viral genotype and patient ethnicity, and that only one in ...

  09 January 2013 | Michael Carter

• Liver cancer has a more aggressive disease course in HIV-positive people co-infected with viral hepatitis

  Co-infection with HIV and viral hepatitis is associated with a more aggressive disease course for liver cancer, according to research conducted in London and presented to the recent EASL Monothematic Conference: HIV and the Liver. The investigators found that liver ...

  18 December 2012 | Michael Carter

• Adding pegylated interferon to entecavir improves hepatitis B treatment response

  Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a presentation at The Liver Meeting 2012, the 63rd Annual ...

  13 December 2012 | Liz Highleyman

More news

Hepatitis B news selected from other sources

• Antiretrovirals Linked to Liver Fibrosis

  Despite hepatitis B virus suppression provided by current drugs, many patients coinfected with hepatitis B and HIV have advanced liver fibrosis, according to new research.

  17 May 2013 | Medscape (requires registration)

• NGO appeals to Health Ministry to support Hepatitis-B

  Long Life Africa (LLA), a health NGO, has appealed to the Ministry of Health and other stakeholders in the sector to work to close the existing gaps in policies and research on Hepatitis-B.

  16 May 2013 | Vibe Ghana

• Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets

  A new analysis from Frost & Sullivan, "Analysis of European Hepatitis B and C Therapeutics Markets" finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period.

  01 May 2013 | PR Newswire

• High maternal viral load key to vertical transmission of hepatitis B

  High maternal viral load is the most important factor causing maternally transmitted hepatitis B virus (HBV) infection and is significantly correlated with e antigen (HBeAg) positivity, according to a prospective study from Taiwan.

  19 March 2013 | Medscape (requires registration)

• Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market

  New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.

  13 March 2013 | PR Newswire (press release)

• NY aims to prevent unsafe injections

  The Safe Injection Practices Coalition, a group of healthcare-related organizations including the CDC indicated since 2001, more than 150,000 patients in the U.S. were told they may have been exposed to hepatitis B, hepatitis C, or human immunodeficiency virus because providers followed unsafe injection procedures.

  12 March 2013 | UPI.com

• Arrowhead data demonstrates RNAi candidate ARC-520 silences hepatitis B virus

  Single injection induces multi-log repression of viral RNA, proteins, and viral DNA; Long duration of effect lasting over 30 days; Regulatory submissions planned for Q2 2013.

  27 February 2013 | Arrowhead Research Corp press release

• FDA rejects Dynavax's adult hepatitis B vaccine on safety concerns

  U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine pending additional data to evaluate its safety, potentially delaying the U.S. market entry of the company's first promising product.

  26 February 2013 | Reuters

• EASL publishes first comprehensive literature review on the burden of liver disease in Europe

  Key findings in the report suggest that alcohol consumption, viral hepatitis B and C and metabolic syndromes related to overweight and obesity are the leading causes of cirrhosis and primary liver cancer in Europe.

  22 February 2013 | Eurekalert Inf Dis

• Study: One-third of hepatitis B and C cases in Pakistan are preventable

  Approximately one-third of all hepatitis B and C cases in Pakistan could be prevented by interventions directed towards a few modifiable risk factors, according to a recent study.

  14 February 2013 | Vaccine News Daily (blog)

More news